Syndax Pharmaceuticals, Inc. Interest Expense Nonoperating
Syndax Pharmaceuticals, Inc. (SNDX) reported Interest Expense Nonoperating of $2.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $2.00K, a 50.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2025 was $6.00K.
- Syndax Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2024 was -$1.00K, a 100.48% decline from fiscal 2023.
- Syndax Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2023 was $208.00K, a 93.37% decline from fiscal 2022.
- Syndax Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2022 was $3.14M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month | Interest Expense Nonoperating 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $2.00K 10-Q · filed 2026-08-04 | $2.00K 10-Q · filed 2026-08-04 | $2.00K derived: sum of 3 quarters · filed 2026-08-04 | $2.00K derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | $0.00 derived: sum of 2 quarters · filed 2026-04-30 | $0.00 derived: sum of 3 quarters · filed 2026-04-30 | $4.00K derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $4.00K derived: sum of 3 quarters · filed 2026-08-04 | $6.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-03 | $4.00K derived: sum of 2 quarters · filed 2026-08-04 | $6.00K 10-Q · filed 2025-11-03 | -$118.00K derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $4.00K 10-Q · filed 2026-08-04 | $6.00K 10-Q · filed 2026-08-04 | -$118.00K derived: sum of 3 quarters · filed 2026-08-04 | -$95.00K derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $2.00K 10-Q · filed 2026-04-30 | -$122.00K derived: sum of 2 quarters · filed 2026-04-30 | -$99.00K derived: sum of 3 quarters · filed 2026-04-30 | -$54.00K derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | -$124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$101.00K derived: sum of 2 quarters · filed 2026-02-26 | -$56.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.00K 10-K · filed 2026-02-26 | $4.93M 10-K · filed 2025-03-03 |
| 2024-09-30 | $23.00K 10-Q · filed 2025-11-03 | $68.00K derived: sum of 2 quarters · filed 2025-11-03 | $123.00K 10-Q · filed 2025-11-03 | $186.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $45.00K 10-Q · filed 2025-08-04 | $100.00K 10-Q · filed 2025-08-04 | $163.00K derived: sum of 3 quarters · filed 2026-02-26 | $233.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $55.00K 10-Q · filed 2025-05-05 | $118.00K derived: sum of 2 quarters · filed 2026-02-26 | $188.00K derived: sum of 3 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $133.00K derived: sum of 2 quarters · filed 2026-02-26 | $208.00K 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $70.00K 10-Q · filed 2024-11-05 | $145.00K 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $3.14M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |